Semaglutide vs Tirzepatide South Africa: Which Weight Loss Injection Is Better in 2026?
South Africa is in the middle of a weight-loss injection revolution. Two drugs -- semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (sold as Mounjaro) -- have transformed how doctors treat obesity worldwide, and both are now increasingly accessible to South African patients. But which one is actually better? And which one should you be asking your doctor about? This guide breaks down the science, the side effects, and the very significant price difference in plain language.
Medical disclaimer: This article is for general information only and does not constitute medical advice. Both semaglutide and tirzepatide are prescription-only medications in South Africa. Consult a registered doctor or endocrinologist before starting any weight-loss medication.
What Are These Medications and How Do They Work?
Both semaglutide and tirzepatide belong to a class of medications called GLP-1 receptor agonists. GLP-1 (glucagon-like peptide-1) is a natural gut hormone that your body releases after eating. It signals to your brain that you are full, slows how quickly your stomach empties, and reduces the liver's glucose output. Injecting a GLP-1 agonist essentially amplifies and extends this "I'm full" signal throughout the day.
Semaglutide targets only the GLP-1 receptor. It was originally developed to treat type 2 diabetes (Ozempic, approved in SA) but doctors and patients quickly noticed dramatic weight loss as a side effect. Wegovy is the higher-dose version approved specifically for weight management in some markets -- though its SA registration status has varied. The once-weekly injection has become one of the most prescribed medications in South Africa.
Tirzepatide goes one step further. It is a dual agonist -- it targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. GIP amplifies the insulin response and appears to enhance how fat cells respond to energy storage signals. The dual action gives tirzepatide a more potent metabolic effect than semaglutide alone. Mounjaro (tirzepatide) received SAHPRA approval for type 2 diabetes in South Africa, with weight management use increasingly common in private practice.
Head-to-Head: Effectiveness for Weight Loss
The clinical trial data tells a clear story. In the SURMOUNT-1 trial (the landmark tirzepatide weight loss study), participants lost:
- Tirzepatide 5 mg: average 15% of body weight over 72 weeks
- Tirzepatide 10 mg: average 19.5% of body weight
- Tirzepatide 15 mg: average 20.9% of body weight
By comparison, the STEP-1 trial (semaglutide 2.4 mg, the Wegovy dose) showed:
- Semaglutide 2.4 mg: average 14.9% of body weight over 68 weeks
The SURMOUNT-5 head-to-head trial published in early 2025 confirmed tirzepatide's edge directly: patients on tirzepatide lost about 47% more weight than those on semaglutide when compared at equivalent time points. For a 100 kg South African patient, that is the difference between losing roughly 15 kg versus 20 kg over the same period.
Bottom line on effectiveness: Tirzepatide wins on raw weight-loss numbers. Both are far more effective than any weight-loss medication that came before them, but tirzepatide's dual mechanism gives it a meaningful edge.
Side Effects: What South African Patients Actually Experience
Both medications share a very similar side-effect profile because both activate GLP-1 receptors. The most common complaints are gastrointestinal:
- Nausea (most common, especially in the first 4-8 weeks)
- Vomiting (less common but more likely at higher doses)
- Diarrhoea or constipation
- Stomach cramps and bloating
- Heartburn or reflux
- Reduced appetite (usually welcome, but can lead to inadequate nutrition if extreme)
Most side effects are worst during the dose-escalation phase (the first few months as your doctor increases your dose gradually) and improve significantly once you reach your maintenance dose. Eating smaller meals, avoiding greasy or spicy food, and staying well hydrated dramatically reduces nausea for most patients.
Rare but serious risks include pancreatitis (inflammation of the pancreas), gallbladder problems, and -- in patients with a personal or family history of certain thyroid cancers -- a theoretical risk of thyroid C-cell tumours based on animal studies (not confirmed in humans). Neither drug should be used during pregnancy.
Muscle loss is a significant concern with both medications. Rapid weight loss from any cause can reduce muscle mass, not just fat. South African doctors increasingly recommend combining these injections with resistance training and high protein intake (1.2-1.6 g protein per kg of body weight daily) to preserve muscle.
Price Comparison in South Africa (ZAR, 2026)
Cost is where the two medications diverge dramatically for South African patients. These drugs are not on the Essential Medicines List and are generally not covered by medical aid for weight loss (coverage for type 2 diabetes management varies by plan).
| Medication | Brand | Dose | Approx. Monthly Cost (ZAR) |
|---|---|---|---|
| Semaglutide | Ozempic 0.5 mg | Starter dose | R1,800 - R2,400 |
| Semaglutide | Ozempic 1 mg | Maintenance dose | R2,200 - R3,000 |
| Tirzepatide | Mounjaro 2.5 mg | Starter dose | R3,500 - R4,500 |
| Tirzepatide | Mounjaro 10-15 mg | Higher maintenance dose | R5,000 - R7,000 |
Prices vary between pharmacies (Dis-Chem, Clicks, and independent dispensing doctors) and fluctuate with exchange rate and stock availability. Compound pharmacy versions (compounded semaglutide or tirzepatide) are available in South Africa at lower cost but quality and dosing accuracy are less regulated -- discuss this carefully with your doctor. Always buy from a registered pharmacy or dispensing doctor, never from online marketplaces or social media sellers.
Medical Aid Coverage in South Africa
Medical aid coverage for these medications remains limited and inconsistent in 2026. Most schemes cover semaglutide (Ozempic) for the management of type 2 diabetes at appropriate prescription benefit (PMB) level. Cover for weight management (obesity) without diabetes is rare and usually requires application through a chronic disease management programme.
Discovery Health, Momentum, and Bonitas members with diagnosed type 2 diabetes may find Ozempic covered at a portion of the cost. Check your plan's chronic medicine benefit directly. Tirzepatide (Mounjaro) coverage is less established -- check with your scheme administrator.
If you do not have medical aid, the out-of-pocket cost makes semaglutide significantly more accessible than tirzepatide for most South African households.
Who Is Each Medication Better Suited For?
Consider semaglutide (Ozempic/Wegovy) if you:
- Have type 2 diabetes and want a medication with strong glucose control AND weight loss
- Have cardiovascular disease -- semaglutide has proven cardiovascular benefit in the LEADER and SELECT trials
- Are budget-constrained -- semaglutide is meaningfully cheaper
- Want the medication with the longest safety track record (semaglutide has been used clinically since 2017)
- Are new to injectable weight-loss medication and want to start with the more established option
Consider tirzepatide (Mounjaro) if you:
- Have tried semaglutide and not achieved adequate weight loss
- Have type 2 diabetes with poor glucose control -- tirzepatide is exceptionally effective at lowering HbA1c
- Have significant obesity (BMI above 35) and want maximum possible weight loss
- Can afford the higher monthly cost without financial strain
- Have been advised by your doctor that the dual mechanism is better suited to your metabolic profile
What About Availability and Stock?
South Africa has experienced significant stock shortages of both medications at various points, driven by global demand outstripping supply. In 2026, availability has improved but can still be inconsistent at individual pharmacy level. Ask your dispensing pharmacist or doctor to check stock across multiple suppliers if your usual pharmacy is out of stock. Avoid panic-buying or purchasing from unregulated sources.
The Bottom Line
Both semaglutide and tirzepatide are genuinely remarkable medications that have changed what is possible in obesity medicine. Tirzepatide is more effective on paper, but semaglutide is better established, cheaper, and has cardiovascular trial data behind it. For most South Africans, semaglutide is the pragmatic starting point. For those who can afford tirzepatide and want maximum results -- or who have not responded adequately to semaglutide -- Mounjaro is a compelling upgrade.
Most importantly: neither medication works as a standalone solution. The best results come from combining these injections with sustainable dietary changes, regular physical activity, and medical supervision. They suppress appetite -- but they cannot teach you new habits. That part is still on you.
Next step: Book an appointment with a registered general practitioner or endocrinologist to discuss whether you are a suitable candidate for GLP-1 therapy. Bring a list of your current medications and any relevant medical history. These drugs require proper screening -- do not source them without a prescription.